DEA
MRNA icon

DoubleLine ETF Adviser’s Moderna MRNA Stock Holding History

DoubleLine ETF Adviser’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$215K Buy
+4,226
New +$197K 0.08% 167

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DoubleLine ETF Adviser's MRNA Position: Q1 2026 in Review

DoubleLine ETF Adviser opened a new position in Moderna (MRNA) in Q1 2026: 4,226 shares worth $215K. The stake represents 0.08% of the portfolio and ranks #167 among its holdings.

722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • DoubleLine ETF Adviser held 4,226 shares of Moderna worth $215K as of Q1 2026.
  • Moderna was a new DoubleLine ETF Adviser position in Q1 2026.
  • Moderna made up 0.08% of DoubleLine ETF Adviser's portfolio in Q1 2026, its #167 holding.
  • 722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on DoubleLine ETF Adviser's 13F filing for Q1 2026, filed 15 May 2026.